BiotechTube

sufficient dose of rocuronium + sugammadex 10 min after position change

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Neuromuscular Blockade

Conditions

Neuromuscular Blockade, Surgery, Anesthesia, Spinal Diseases

Trial Timeline

May 15, 2016 → Feb 16, 2017

NCT ID
NCT02724111

About sufficient dose of rocuronium + sugammadex 10 min after position change

sufficient dose of rocuronium + sugammadex 10 min after position change is a approved stage product being developed by Merck for Neuromuscular Blockade. The current trial status is completed. This product is registered under clinical trial identifier NCT02724111. Target conditions include Neuromuscular Blockade, Surgery, Anesthesia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02724111ApprovedCompleted

Competing Products

20 competing products in Neuromuscular Blockade

See all competitors
ProductCompanyStageHype Score
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
52
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
52
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
52
Placebo + Sugammadex + Esmeron®MerckPhase 2
52
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
85
Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
85
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + NeostigmineMerckPre-clinical
23
Sugammadex + RocuroniumMerckApproved
85
neostigmine/glycopyrrolate + sugammadexMerckApproved
85
sugammadexMerckPhase 3
77
2 mg/kg sugammadex + 0.07 mg/kg neostigmineMerckPhase 3
77
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
85
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved
85
Sugammadex + NeostigmineMerckApproved
85
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or VecuroniumMerckApproved
85
sugammadex + Neostigmine + GlycopyrrolateMerckApproved
85
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;MerckPhase 2
52
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
85
Rocuronium Bromide + Rocuronium BromideMerckApproved
85
Rocuronium (moderate NMB) + Rocuronium (deep NMB)MerckPre-clinical
23

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85